A PHASE 2, OPEN LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF TAS-116 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER DISEASE PROGRESSION ON, OR INTOLERANCE TO IMATINIB, SUNITINIB AND REGORAFENIB

Trial Profile

A PHASE 2, OPEN LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF TAS-116 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER DISEASE PROGRESSION ON, OR INTOLERANCE TO IMATINIB, SUNITINIB AND REGORAFENIB

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs TAS 116 (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 03 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 16 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top